<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631146</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG2004</org_study_id>
    <nct_id>NCT04631146</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Camrelizumab in Real-World Study</brief_title>
  <official_title>Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Retrospective, Observational, Multicenter Real-World Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational real-world study is designed to evaluate the efficacy and safety of&#xD;
      camrelizumab for the treatment of Chinese NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Camrelizumab is a humanized antibody for cancer immunotherapy. The National Medical Products&#xD;
      Administration (NMPA, China) approved camrelizumab as a first-line treatment of certain&#xD;
      patients with NSCLC.&#xD;
&#xD;
      This is a multicenter non-interventional study, NSCLC patients who have been treated with&#xD;
      camrelizumab will be included. The main objective of this study is to evaluate the efficacy&#xD;
      and safety of camrelizumab in the clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant therapy population: pathological complete response rate (pCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R0 resection rate.</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant therapy population: R0 resection rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Advanced non-small cell lung cancer: objective response rate (ORR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month PFS%</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Advanced non-small cell lung cancer: 6-month progression-free survival rate (PFS%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MPR</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant population: main pathological response rate (MPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative rate</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant population: operative rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perioperative mortality</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant population: perioperative mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of major postoperative complications</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Neoadjuvant population: incidence of major postoperative complications (within 30 days after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iORR</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>First-line combined treatment population: median treatment cycle number, intracranial objective response rate (iORR) in patients with brain metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iPFS</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>First-line combined treatment population: median treatment cycle number, intracranial progression-free survival (iPFS) in patients with brain metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Safety of the general population: Adverse Events (AE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>From August 1, 2019 to June 31, 2021</time_frame>
    <description>Safety of the general population: Serious Adverse Events (SAE).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab-treated advanced NSCLC</arm_group_label>
    <description>Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>PD-1 inhibitors</description>
    <arm_group_label>Camrelizumab-treated advanced NSCLC</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Total 450 patients who have received camrelizumab with NSCLC will be enrolled. The patients&#xD;
        should be registered consecutively in each site.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years old;&#xD;
&#xD;
          2. Histopathological diagnosed confirmed non-small cell lung cancer;&#xD;
&#xD;
          3. Have received at least one camrelizumab injection between August 1, 2019 and December&#xD;
             31, 2020;&#xD;
&#xD;
          4. Traceable cases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received other immunotherapy at the same time;&#xD;
&#xD;
          2. Patients who were participating in other intervention studies;&#xD;
&#xD;
          3. Patients with other malignant tumors;&#xD;
&#xD;
          4. The researcher believes that the patient is not suitable to participate in this study&#xD;
             with any other conditions .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wu Yilong, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Chongrui, Doctor</last_name>
    <phone>+8618696164925</phone>
    <email>xucr001@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chongrui Xu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Yi-Long Wu, MD</last_name>
      <phone>+86 20 83827812</phone>
      <phone_ext>51221</phone_ext>
      <email>syylwu@live.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yilong Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chongrui Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

